JCR Pharmaceuticals has received conditional marketing authorization for IZCARGO in Kuwait, its second market outside Japan. The blood-brain barrier-penetrating enzyme therapy is designed to address both systemic and neurological features of Hunter syndrome, although its global Phase 3 programme remains ongoing.
Estrella has added Intermountain Health LDS Hospital as the fifth site in its Phase 1/2 STARLIGHT-1 study of EB103. Earlier testing found complete responses in five evaluable patients at the higher dose, but the small uncontrolled dataset and the company's financing position remain important development considerations.
The FDA has expanded ANKTIVA plus BCG to adults with BCG-unresponsive high-grade papillary-only non-muscle-invasive bladder cancer. The decision relies on existing clinical evidence and biological similarities with carcinoma in situ, rather than a new pivotal efficacy result specifically demonstrating treatment benefit in papillary-only patients.
Altay Therapeutics has closed a $37 million Series A financing to advance DX5057, an investigational oral DUX4 inhibitor for facioscapulohumeral muscular dystrophy. The company expects to begin Phase 1 testing in early 2027, following preclinical evidence of reduced muscle injury and preserved function.
Celltrion will highlight long-term and real-world evidence for Remsima SC at UEG Week 2026 in Barcelona, alongside its recently introduced liquid intravenous formulation and wider IBD biosimilar portfolio. The programme reinforces a commercialization strategy supported by randomized maintenance studies, although the conference announcement does not disclose new efficacy results.
Takeda has begun selling ORZEYFUL in Japan and China, introducing the first approved orexin receptor 2 agonist for narcolepsy type 1. Two Phase 3 studies involving 273 patients demonstrated substantial improvements in wakefulness and cataplexy, while the planned US launch remains dependent on controlled-substance scheduling.
Alentis Therapeutics and PinotBio have signed a research and licensing agreement to develop new claudin-1-targeting antibody-drug conjugates. The partnership adds linker and payload options to a pipeline already containing two clinical-stage ADCs, although financial terms and new product candidates remain undisclosed.
Galderma has agreed to acquire ZO Skin Health from investors including Blackstone and the Obagi family for an enterprise value of $1.5 billion. The transaction adds approximately $330 million in annual sales and a network of more than 16,500 professional accounts, although near-term integration spending is expected to weigh on margins.
Jocasta Neuroscience and Diamond Therapeutics will evaluate three psychedelic-inspired 5-HT2A receptor compounds for cognitive impairment and neurodegeneration. The agreement gives Jocasta an option to license successful candidates, but the molecules have not yet demonstrated clinical efficacy or an absence of hallucinogenic effects in humans.
Anixa's ovarian cancer CAR-T inventor will deliver a November keynote as lira-cel advances through Phase 1 dose escalation. Preliminary findings include four patients surviving more than one year and an initial 90-day stable disease observation, but controlled efficacy evidence is not yet available.